Nebenwirkungen · Ituxredi
Ituxredi 100 mg concentrate for solution for infusion Ituxredi 500 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 21
HOS-152144 · Präparat HOS-100701
A total of 309 paediatric patients received rituximab and were included in the safety analysis population. Paediatric patients randomised to the LMB chemotherapy arm with rituximab, or enrolled in the single arm part of the study, were administered rituximab at a dose of 375 mg/m2 BSA and received a total of six IV infusions of rituximab (two during each of the two induction courses and one during each of the two consolidation courses of the LMB scheme).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-09T10:02:28Z · SHA-256 65f947c73c59460b3d1812ff80010d6719d500cc410ebccf88cf20b48b9c9fe9 · Passage 21484019ff3ccb96407b3e9a19cb797743c8f21bd63981180c71f0e245e488d2 · Zeichen 24424–24882 im Abschnitt